Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.9
5.2
Journals
Vaccines
Special Issues
Neutralizing Antibody Response against SARS-CoV-2
share announcement

Neutralizing Antibody Response against SARS-CoV-2

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccine Efficacy and Safety".

Deadline for manuscript submissions: closed (31 August 2023) | Viewed by 5839

Special Issue Editors

Dr. Lalit Batra

E-Mail Website
Guest Editor
Regional Biocontainment Laboratory (RBL), Center for Predictive Medicine, University of Louisville, Louisville, KY 40292, USA
Interests: infection and immunity; immunotherapy; check-point inhibitors and stimulators; T cell response against SARS-CoV-2; viral immunity; translational research; clinical trials; bacterial and viral vaccines; immune mechanism behind antivirals; host-pathogen immunology
Special Issues, Collections and Topics in MDPI journals
Dr. Divyasha Saxena

E-Mail Website
Guest Editor
Center for Predictive Medicine (CPM), Clinical Translational Research Building (CTRB), 505 South Hancock Street, Rm#626A, Louisville, KY 40222, USA
Interests: vaccination against SARS-CoV-2; antiviral research; host–pathogen interaction
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Serum-neutralizing antibodies appear after natural infection or vaccination or both, and are maintained as memory for several months. Antibodies are the best available correlate of protection against re-infection with other variants of concerns. Newly emerged SARS-CoV-2 omicron variants (BA.1, BA.1.1, BA.2, BA.2.H78Y, BA.3, BA.4, and BA.5) have raised serious concerns over neutralizing antibody responses due to a high number of mutations in viral spike glycoprotein, suggesting possible immune evasion. We are pleased to invite you to submit to this Special Issue for all kinds of manuscripts, such as research articles, brief reports, and communications to promote the knowledge and discussion. The manuscripts should include the virus neutralization data (live virus or surrogate assays) on sera samples from healthy/immune-compromised individuals with a background of vaccination against SARS-CoV-2, natural infection, or both.

We look forward to your contributions.

Dr. Lalit Batra
Dr. Divyasha Saxena
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • SARS-CoV-2
  • COVID-19 vaccines
  • breakthrough infection
  • neutralization
  • immune evasion
  • microneutralization/PRNT assay

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

28 pages, 3577 KiB  
Review
S Protein, ACE2 and Host Cell Proteases in SARS-CoV-2 Cell Entry and Infectivity; Is Soluble ACE2 a Two Blade Sword? A Narrative Review
by Reza Nejat, Maziar Fayaz Torshizi and David J. Najafi
Vaccines 2023, 11(2), 204; https://doi.org/10.3390/vaccines11020204 - 17 Jan 2023
Cited by 11 | Viewed by 4976
Abstract
Since the spread of the deadly virus SARS-CoV-2 in late 2019, researchers have restlessly sought to unravel how the virus enters the host cells. Some proteins on each side of the interaction between the virus and the host cells are involved as the [...] Read more.
Since the spread of the deadly virus SARS-CoV-2 in late 2019, researchers have restlessly sought to unravel how the virus enters the host cells. Some proteins on each side of the interaction between the virus and the host cells are involved as the major contributors to this process: (1) the nano-machine spike protein on behalf of the virus, (2) angiotensin converting enzyme II, the mono-carboxypeptidase and the key component of renin angiotensin system on behalf of the host cell, (3) some host proteases and proteins exploited by SARS-CoV-2. In this review, the complex process of SARS-CoV-2 entrance into the host cells with the contribution of the involved host proteins as well as the sequential conformational changes in the spike protein tending to increase the probability of complexification of the latter with angiotensin converting enzyme II, the receptor of the virus on the host cells, are discussed. Moreover, the release of the catalytic ectodomain of angiotensin converting enzyme II as its soluble form in the extracellular space and its positive or negative impact on the infectivity of the virus are considered. Full article
(This article belongs to the Special Issue Neutralizing Antibody Response against SARS-CoV-2)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop